I-Mab Biopharma expands collaboration with WuXi Biologics

27 September 2018

China’s WuXi Biologics (HK: 2269) and biotech firm I-Mab Biopharma have expanded their strategic collaboration and licensed proprietary WuXiBody Platform to develop three bispecific antibodies (Bsab). WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics.

Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline. WuXi Biologics will receive an undisclosed upfront payment as well as development, regulatory and commercial milestone payments, and will be entitled to royalties based on global sales of these bispecific antibodies.

In July this year, I-Mab Biopharma also signed a deal with Korea's ABL Bio Corporation focusing on bispecific antibodies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK